Clinical trial NCT00959972 - References

Coronary Heart Disease — Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease

Citation(s)

•   Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, Williams KE, Reeves KR
  Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008 Aug;63(8):717-24. doi: 10.1136/thx.2007.090647. Epub 2008 Feb 8.
•   Critchley J, Capewell S
  Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2003;(4):CD003041. Review. Update in: Cochrane Database Syst Rev. 2004;(1):CD003041.
•   Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group
  Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):47-55.
•   Meine TJ, Patel MR, Washam JB, Pappas PA, Jollis JG
  Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol. 2005 Apr 15;95(8):976-8.
•   Pipe A
  Smoking. Can J Cardiol. 1999 Dec;15 Suppl G:77G-80G. Review.
•   Reid RD, Pipe AL, Quinlan B
  Promoting smoking cessation during hospitalization for coronary artery disease. Can J Cardiol. 2006 Jul;22(9):775-80.
•   Rigotti NA, Munafo MR, Stead LF
  Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001837. Review. Update in: Cochrane Database Syst Rev. 2012;5:CD001837.

Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease: a Pilot Randomized Trial

Details for clinical trial NCT00959972